Reapplix is a regenerative medicine company offering a new solution to an old challenge.
Our mission is to change the life of patients with non-healing wounds by providing them with a new role in the management of their own wound.
Our promise is to provide clinicians with the tools to harness the patients’ own power from the patients’ blood without additional additives. We offer a proven alternative to other available wound management solutions such as those derived from donated cultured cells, human cadavers, placentas or animal derived collagen.
Reapplix was founded in 2008 by leading inventors and scientists and now offers a new solution for the treatment of chronic wounds such as diabetic foot ulcers. Based in Denmark, with sales teams in the US, UK and Germany, the innovative 3C Patch® is backed by strong clinical evidence and is now available for the benefit of patients and healthcare practitioners.
New Publication in The Lancet Diabetes & Endocrinology
The positive outcome data of an independent Randomized Controlled Trial (RCT) of 3C Patch® was published in The Lancet Diabetes & Endocrinolocy on September 19, 2018.1 The results have also been presented at many scientific meetings in USA and Europe including the American Diabetes Association 78th Scientific Sessions meeting, June 2018, the Diabetic Foot Study Group Conference September 2018, and at the annual meeting of the European Association for the Study of Diabetes (EASD), October 2018.
1. Game F., Jeffcoate W., Tarnow L., Jacobsen JL., Whitham DJ., Harrison EF., Ellender SJ., Fitzsimmons D., Löndahl M., LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden:an observer-masked randomized controlled trial. www.thelancet.com/diabetes-endocrinology. Published online September 19, 2018 https://www.thelancet.com/journals/landia/article/PIIS2213-8587(18)30240-7/fulltext